ANI Pharmaceuticals (NASDAQ: ANIP) investors back directors, pay and stock plan
ANI Pharmaceuticals (NASDAQ: ANIP) stockholders approved all proposals at their 2026 Annual Meeting, including the election of seven directors, ratification of Ernst & Young LLP as auditor, and advisory approval of executive compensation. They also approved the Amended and Restated 2022 Stock Incentive Plan and opted for annual advisory votes on executive pay. The meeting's results, detailing voting figures for each proposal, reinforce investor confidence in the company's governance and compensation practices.
APR 17·MarketBeat▲
ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded by Zacks Research to Strong-Buy Rating
Zacks Research has upgraded ANI Pharmaceuticals (NASDAQ:ANIP) from a "hold" to a "strong-buy" rating, despite recent insider selling. Analysts currently maintain a "Moderate Buy" consensus with a target price of $107.33, though Guggenheim recently raised its target to $124. The stock opened at $78.07, and institutional investors have also adjusted their positions in the company.
APR 13·The Manila Times▲
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
ANI Pharmaceuticals has announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg, and 300 mg, a generic version of Carbatrol®. This launch strengthens ANI's Generics portfolio and aims to improve patient access to essential medicines. The U.S. annual sales for this product are approximately $65 million based on recent IQVIA data.
